ARTICLE | Clinical News
RP6530: Phase I started
December 23, 2013 8:00 AM UTC
Rhizen began an open-label, dose-escalation, Italian Phase I trial to evaluate twice-daily oral RP6530 in up to 42 patients. ...
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Rhizen began an open-label, dose-escalation, Italian Phase I trial to evaluate twice-daily oral RP6530 in up to 42 patients. ...